The Medical Letter

In Brief: Removal of Suicidality Warning from GLP-1 Agonists for Weight Management https://secure.medicalletter.org/TML-article-1748e

Advance Release In Brief: Rybelsus R2 Rebranded as Ozempic https://bit.ly/4atb4ix

In Brief: New Warning for Injectable Medroxyprogesterone https://secure.medicalletter.org/TML-article-1747e

It’s Trivia Tuesday! This question is from our article Risks of Tramadol and Gabapentin Use for Pain https://medicalletter.org/tragab747d

Answer: b
Tramadol is available alone and in a fixed-dose combination with acetaminophen. It is classified as a Schedule IV controlled substance.

In Brief: Label Changes for Menopausal Hormone Therapy Products
https://secure.medicalletter.org/TML-article-1748d

Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks https://medicalletter.org/sebet748c

A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
https://medicalletter.org/trepr748b

Aztreonam/Avibactam (Emblaveo) for Complicated Intra-Abdominal Infections
https://medicalletter.org/embla748a

Read our latest issue https://bit.ly/4aaZ1WS

#cIAI #pulmonaryhypertension #HAE #menopause #GLP1

Answer: d
Use of gepotidacin should be avoided in patients with a history of QT-interval prolongation, in those with relevant pre-existing cardiac disease, and in those taking antiarrhythmics or other drugs that prolong the QT interval.

It’s Trivia Tuesday! This question is from our article Gepotidacin (Blujepa) - A New Antibiotic for Uncomplicated UTI medicalletter.org/gepo745a

New Warning for Injectable Medroxyprogesterone secure.medicalletter.org/TML-article-...

Removal of Suicidality Warning from GLP-1 Agonists for Weight Management
Advance Release Article: bit.ly/3ZEZwUc

#GLP1 #weightmanagement

Risks of Tramadol and Gabapentin Use for Pain medicalletter.org/tragab747d

Lumateperone (Caplyta) for Adjunctive Treatment of Depression medicalletter.org/lumat747c

Elecsys — A Second Blood Test for Alzheimer's Disease medicalletter.org/elecs747b

Sublingual cyclobenzaprine has a faster onset of action but a shorter duration of action than the oral formulations. (2/2)

Answer: b
Sublingual administration of cyclobenzaprine bypasses first-pass hepatic metabolism, resulting in reduced exposure to the active metabolite norcyclobenzaprine and fewer anticholinergic adverse effects than oral immediate-release cyclobenzaprine. (1/2)

It’s Trivia Tuesday! This question is from our article Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia bit.ly/3YZ3aIp

Oral Semaglutide (Wegovy) for Weight Loss medicalletter.org/semag747a

Uzedy, an extended-release, SC formulation of the second-generation antipsychotic drug risperidone, has now been approved for use as monotherapy or in combination with lithium or valproate for maintenance treatment of bipolar I disorder in adults.
secure.medicalletter.org/TML-article-...

Imlunestrant (Inluriyo) for Advanced Breast Cancer medicalletter.org/imlu746d

Answer: d
Rash and mild injection-site reactions have also occurred. Very low LDL-C levels due to PCSK9 inhibitor use have not been associated with adverse clinical effects.

It’s Trivia Tuesday! This question is from our article Expanded Indication for PCSK9 Inhibitors medicalletter.org/pcsk744a

Donidalorsen (Dawnzera) for Prevention of Hereditary Angioedema Attacks medicalletter.org/donid746c

Zurnai, an autoinjector formulation of the opioid antagonist nalmefene, has been approved by the FDA for IM or SC emergency treatment of known or suspected opioid overdose in persons ≥12 years old medicalletter.org/nalme746b

The FDA has approved Tonmya (Tonix), a sublingual tablet formulation of the skeletal muscle relaxant cyclobenzaprine, for treatment of fibromyalgia in adults
medicalletter.org/cyclo746a

Read our latest issue: secure.medicalletter.org/TML-issue-1746

#Fibromyalgia #OpioidOverdose #HAE #BreastCancer

Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI medicalletter.org/gepo745a

Read our latest issue: bit.ly/4jhEzHY